Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-COMP versus R-CHOP in elderly patients with newly diagnosed non-localised DLBCL or follicular lymphoma grade IIIb
2013-001065-17Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of doxorubicin, rituximab, cyclophosphamide, vincristine and prednisone in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by GELTAMO. Primary endpoint: Subclinical cardiac toxicity. Started Jun 2013; status: completed.
02
Drugs
doxorubicinrituximabcyclophosphamidevincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2013-001065-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001065-17.